Robert Brenner, the Chief Medical Officer of $VERA, sold 2,151 shares of the company on 02-23-2026 for an estimated $90,307. We received data on the trade from a recent SEC filing. This was a sale of approximately 4.1% of their shares of this class of stock. Following this trade, they now own 50,947 shares of this class of $VERA stock.
$VERA Insider Trading Activity
$VERA insiders have traded $VERA stock on the open market 13 times in the past 6 months. Of those trades, 1 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $VERA stock by insiders over the last 6 months:
- WILLIAM D. TURNER (Chief Regulatory Officer) has made 0 purchases and 4 sales selling 32,187 shares for an estimated $1,445,638.
- MARSHALL FORDYCE (PRESIDENT AND CEO) sold 16,925 shares for an estimated $710,577
- JOSEPH R YOUNG (SVP, FINANCE, CHIEF ACCT OFFCR) has made 0 purchases and 2 sales selling 18,117 shares for an estimated $566,738.
- PATRICK G ENRIGHT purchased 5,882 shares for an estimated $249,985
- SEAN GRANT (CHIEF FINANCIAL OFFICER) sold 4,949 shares for an estimated $207,778
- DAVID LEE JOHNSON (Chief Operating Officer) sold 2,579 shares for an estimated $108,276
- JASON S CARTER (Chief Legal Officer) sold 3,864 shares for an estimated $107,498
- ROBERT BRENNER (Chief Medical Officer) sold 2,151 shares for an estimated $90,307
- LAURENCE MATTHEW SKELTON (Chief Commercial Officer) sold 1,582 shares for an estimated $66,418
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$VERA Hedge Fund Activity
We have seen 136 institutional investors add shares of $VERA stock to their portfolio, and 100 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEEP TRACK CAPITAL, LP added 2,821,135 shares (+inf%) to their portfolio in Q4 2025, for an estimated $142,862,276
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,795,537 shares (+49.0%) to their portfolio in Q4 2025, for an estimated $90,925,993
- BELLEVUE GROUP AG added 1,698,152 shares (+inf%) to their portfolio in Q4 2025, for an estimated $85,994,417
- TANG CAPITAL MANAGEMENT LLC removed 1,350,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $68,364,000
- HOLOCENE ADVISORS, LP added 1,307,393 shares (+inf%) to their portfolio in Q4 2025, for an estimated $66,206,381
- ALLIANCEBERNSTEIN L.P. added 1,166,066 shares (+2217.2%) to their portfolio in Q4 2025, for an estimated $59,049,582
- CITADEL ADVISORS LLC removed 837,850 shares (-51.9%) from their portfolio in Q4 2025, for an estimated $42,428,724
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$VERA Analyst Ratings
Wall Street analysts have issued reports on $VERA in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Buy" rating on 12/19/2025
- Goldman Sachs issued a "Buy" rating on 12/19/2025
- JP Morgan issued a "Overweight" rating on 12/19/2025
- TD Cowen issued a "Buy" rating on 12/05/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/10/2025
To track analyst ratings and price targets for $VERA, check out Quiver Quantitative's $VERA forecast page.
$VERA Price Targets
Multiple analysts have issued price targets for $VERA recently. We have seen 7 analysts offer price targets for $VERA in the last 6 months, with a median target of $90.0.
Here are some recent targets:
- Dina Ramadane from B of A Securities set a target price of $66.0 on 12/19/2025
- Paul Choi from Goldman Sachs set a target price of $95.0 on 12/19/2025
- Anupam Rama from JP Morgan set a target price of $96.0 on 12/19/2025
- Laura Chico from Wedbush set a target price of $33.0 on 12/11/2025
- Gavin Clark-Gartner from Evercore ISI Group set a target price of $97.0 on 12/08/2025
- Ritu Baral from TD Cowen set a target price of $73.0 on 12/05/2025
- Arthur He from HC Wainwright & Co. set a target price of $90.0 on 11/10/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
